Moreover, the strong upregulation of Sdc-3 on tumor versus normal tissue indicates that this molecule could be exploited as a tumor-associated antigen in approaches based on cell therapy or antibody drug conjugates. This evidence concerns the gene SDC3 and neoplasm.